Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PET imaging · 1 trial · 1 indication
Comparing the sensitivity of 18 F-DCFPyL-PET/CT and FDG PET/CT in metastatic lesion detection in triple-negative breast cancer patients.
| Arm | Type | Description |
|---|---|---|
| PET Imaging of breast cancer patients | EXPERIMENTAL | Triple negative breast cancer patients will undergo FDG PET/CT and Pyl PET/Ct |
| Name | Type | Description |
|---|---|---|
| PET imaging | DIAGNOSTIC_TEST | Imaging with FDG PET/CT and Pyl PET/CT in triple negative breast cancer |
Inclusion Criteria: * Female \>= 18 years of age * Patients in distantly metastatic TNBC based on the initial diagnosis biopsy. * Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included. Exclusion Criteria: * Patients with know...
PET imaging is being studied as a diagnostic tool in Triple Negative Breast Cancer. It is an investigational imaging approach in early clinical development, with a Phase 1 trial currently recruiting patients. The study aims to evaluate its use in this specific cancer type, though it is not yet approved for this indication.
PET imaging is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker LNTH. The company is conducting clinical research on this imaging modality for use in Triple Negative Breast Cancer, with the development currently in Phase 1.
PET imaging is in Phase 1 clinical development for Triple Negative Breast Cancer. It is an investigational imaging agent, not yet approved by regulatory authorities. A single early Phase 1 trial is currently recruiting participants in the United States to assess its application in this patient population.
PET imaging is being evaluated in one clinical trial, NCT06586047, titled "Breast Cancer PSMA PET." This early Phase 1 study is recruiting 30 female patients aged 18 years and older with Triple Negative Breast Cancer in the United States. The trial is uncontrolled and not randomized or double-blinded.
PET imaging in this context refers to the imaging technique being studied, and the clinical trial is specifically titled "Breast Cancer PSMA PET." The trial evaluates PSMA-targeted PET imaging in Triple Negative Breast Cancer. The drug name provided is PET imaging, and the trial focuses on PSMA PET imaging.